This article is more than 5 years old. Information may no longer be current.
Eli Lilly obtains rights to intranasal glucagon from Locemia Solutions
Click Here to Manage Email Alerts
Worldwide rights to Locemia Solutions’ intranasal glucagon were granted to Eli Lilly, according to a company press release.
Glucagon nasal powder, currently in phase 3 clinical trial testing, may be the first rescue treatment for severe hypoglycemia to be needle-free.
“If approved, glucagon nasal powder would be an important innovation for people with diabetes and an exciting addition to our product portfolio,” Enrique Conterno, president of Lilly Diabetes, said in the release. “Administration of glucagon is critical when people with diabetes experience a severe hypoglycemic episode, and in an emergency situation, not having to reconstitute or inject the medicine would reduce the complexity in an already stressful situation. We look forward to bringing this product to market.”
The formulation would be delivered in a single-use, ready-to-use device and would provide emergency care for patients experiencing severe hypoglycemia.
“Locemia’s mission has been to find an innovative approach to make severe hypoglycemia rescue simple,” Claude Piché, DVM, MSc, CEO of Locemia Solutions, said in the release. “We believe needle-free glucagon nasal powder could positively impact the lives of those who use insulin and expand the community of people who could take action in a severe hypoglycemia emergency.”